if you were a long time shareholder you would know the royalty rate was negotiated many years ago before the technology was proven and you would also know the current CEO had nothing to do with the negotiation. Dan did not lie to the shareholders, but he could have handled the questions better since this was not new information. This (IMO) was a planned attack aided by the analysts on the call. Shorts win because they were in major pain, institutions that wanted in at a lower price are happy, only the long term owners lose. Time will tell, but I say this opportunity is similar to the $5 stock available after the Roche FDA T-DM1 turn down.
Bioimmune, we are on the same side and I appreciate your posts. I think it was misleading for Junius to proclaim that they were flush with funds, like on Cramer, then dilute us, even if they got a good price for the shares. I know the royalty rate is pre-Junius, but Mitch was a straight shooter. My point was that the CEO has an obligation, even to us retail nobodies, to be straightfoward. Its great to promote the stock, but should be done with vision, not deception.